ArticleAntimicrobial agents and chemotherapy1999
Multiple novel inhibitors of the NorA multidrug transporter of Staphylococcus aureus.
Article in Antimicrobial agents and chemotherapy, 1999. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 64 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
64 citing papers in PubMed, 214 citations in OpenAlex.
- Designing Antibiotics with Inherent Resistance to Efflux as a Strategy to Revive Discovery against Multidrug-Resistant Pathogens.Journal of medicinal chemistry · 2026Article
- Unlocking the Gates: A Novel Diagnostic Molecule for Quantifying Efflux Levels in Gram-Positive Bacteria.Advanced healthcare materials · 2025Article
- Repurposing of dibucaine and niflumic acid as antimicrobial agents in combination with antibiotics against Staphylococcus aureus.The Journal of antibiotics · 2024Article
- Crotamine derived from Crotalus durissus terrificus venom combined with drugs increases in vitro antibacterial and antifungal activities.Archives of microbiology · 2024Article
- Comparative Antibacterial and Efflux Pump Inhibitory Activity of Isolated Nerolidol, Farnesol, and α-Bisabolol Sesquiterpenes and Their Liposomal Nanoformulations.Molecules (Basel, Switzerland) · 2023Article
- Valencene, Nootkatone and Their Liposomal Nanoformulations as Potential Inhibitors of NorA, Tet(K), MsrA, and MepA Efflux Pumps inPharmaceutics · 2023Article
- Role of bacterial efflux pumps in antibiotic resistance, virulence, and strategies to discover novel efflux pump inhibitors.Microbiology (Reading, England) · 2023Review
- Riparin-B as a Potential Inhibitor of AdeABC Efflux System fromEvidence-based complementary and alternative medicine : eCAM · 2023Article
- Phenolic Compound Ethyl 3,4-Dihydroxybenzoate Retards Drug Efflux and Potentiates Antibiotic Activity.Antibiotics (Basel, Switzerland) · 2022Article
- Dynamic Boolean modelling reveals the influence of energy supply on bacterial efflux pump expression.Journal of the Royal Society, Interface · 2022Article
- Medicinal Chemistry of Inhibitors Targeting Resistant Bacteria.Current topics in medicinal chemistry · 2022Article
- Modulation of Drug Resistance by Furanochromones inEvidence-based complementary and alternative medicine : eCAM · 2022Article
- A Double-Edged Sword: Thioxanthenes Act on Both the Mind and the Microbiome.Molecules (Basel, Switzerland) · 2021Review
- Microbial Efflux Pump Inhibitors: A Journey around Quinoline and Indole Derivatives.Molecules (Basel, Switzerland) · 2021Review
- Chemical composition and potentiating action of Norfloxacin mediated by the essential oil of Piper caldense C.D.C. against Staphylococcus aureus strains overexpressing efflux pump genes.Archives of microbiology · 2021Article
- Development of an Antibiotic Resistance Breaker to Resensitize Drug-ResistantFrontiers in cellular and infection microbiology · 2021Article
- The Role of Efflux Pumps in the Transition from Low-Level to Clinical Antibiotic Resistance.Antibiotics (Basel, Switzerland) · 2020Article
- Chalcones Isolated fromAntibiotics (Basel, Switzerland) · 2020Article
- Plants againstBiotechnology reports (Amsterdam, Netherlands) · 2020Review
- Drug combinations: a strategy to extend the life of antibiotics in the 21st century.Nature reviews. Microbiology · 2019Review
4 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
Abstract
The multidrug transporter NorA contributes to the resistance of Staphylococcus aureus to fluoroquinolone antibiotics by promoting their active extrusion from the cell. Previous studies with the alkaloid reserpine, the first identified inhibitor of NorA, indicate that the combination of a chemical NorA inhibitor with a fluoroquinolone could improve the efficacy of this class of antibiotics. Since reserpine is toxic to humans at the concentrations required to inhibit NorA, we sought to identify new inhibitors of NorA that may be used in a clinical setting. Screening of a chemical library yielded a number of structurally diverse inhibitors of NorA that were more potent than reserpine. The new inhibitors act in a synergistic manner with the most widely used fluoroquinolone, ciprofloxacin, by substantially increasing its activity against both NorA-overexpressing and wild-type S. aureus isolates. Furthermore, the inhibitors dramatically suppress the emergence of ciprofloxacin-resistant S. aureus upon in vitro selection with this drug. Some of these new inhibitors, or their derivatives, may prove useful for augmentation of the antibacterial activities of fluoroquinolones in the clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.